1. Digitum: Repositorio Institucional de la Universidad de Murcia
  2. Investigación
  3. Artículos
Por favor, use este identificador para citar o enlazar este ítem: https://doi.org/10.1002/jcb.26293

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorFranco, Lia Carolina-
dc.contributor.authorMorales, Fátima-
dc.contributor.authorBoffo, Silvia-
dc.contributor.authorGiordano, Antonio-
dc.date.accessioned2024-09-27T10:13:15Z-
dc.date.available2024-09-27T10:13:15Z-
dc.date.issued2017-07-19-
dc.identifier.citationJournal of Cellular Biochemistry, 2018, Vol. 119, N. 2, pp. 1273-1284es
dc.identifier.issnPrint: 0730-2312-
dc.identifier.issnElectronic: 1097-4644-
dc.identifier.urihttp://hdl.handle.net/10201/144343-
dc.description© 2017 Wiley Periodicals, Inc. This document is the Submitted version of a Published Work that appeared in final form in Journal of Cellular Biochemistry. To access the final edited and published work see https://doi.org/10.1002/jcb.26293es
dc.description.abstractCyclin-Dependent Kinase 9 (CDK9) is part of a functional diverse group of enzymes responsible for cell cycle control and progression. It associates mainly with Cyclin T1 and forms the Positive Transcription Elongation Factor b (p-TEFb) complex responsible for regulation of transcription elongation and mRNA maturation. Recent studies have highlighted the importance of CDK9 in many relevant pathologic processes, like cancer, cardiovascular diseases, and viral replication. Herein we provide an overview of the different pathways in which CDK9 is directly and indirectly involved.es
dc.formatapplication/pdfes
dc.format.extent12es
dc.languageenges
dc.publisherWileyes
dc.relationThis work was supported by the Fund for Sbarro Health Research Organization (SHRO) and for the Italian Association for Cancer Research (Associazione Italiana per la Ricerca sul Cancro, AIRC). The award of a postdoctoral grant from the Martín Escudero Foundation to Fátima Morales is gratefully acknowledged, as well as to the Fundación Seneca-CARM for her Saavedra Fajardo contract and funding (Contract No. 20025/SF/16).es
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCancer pathwayes
dc.subjectCDK9es
dc.subjectCyclines
dc.subjectDrug targetinges
dc.subjectKinasees
dc.subjectTranscription regulationes
dc.subjectViral replicationes
dc.titleCDK9: a key player in cancer and other diseaseses
dc.typeinfo:eu-repo/semantics/articlees
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1002/jcb.26293es
dc.identifier.doihttps://doi.org/10.1002/jcb.26293-
dc.contributor.departmentDepartamento de Química Orgánica-
Aparece en las colecciones:Artículos

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
CDK9 JCB new format_50refs.pdf287,7 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro sencillo del ítem Mostrar el registro PREMIS del ítem  Estadísticas


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons